Ctx and Impurities
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | CTX1 REF: 4Z-C-353001CAS: 501935-96-2 | - - - | To inquire | Mon 31 Mar 25 |
| CTX1-d6 REF: 4Z-C-353002CAS: 501935-96-2 | - - - | To inquire | Mon 31 Mar 25 |
 | BMS-813160 REF: TM-T4584CAS: 1286279-29-5 | 99.66% - 99.78% | 63.00 €~1,644.00 € | Mon 31 Mar 25 |
Ref: 4Z-C-353001
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Monday 31 Mar 2025
Ref: 4Z-C-353002
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Monday 31 Mar 2025
BMS-813160
CAS:1286279-29-5
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
Formula:
C25H40N8O2
Purity:
99.66% - 99.78%
Color and Shape:
Solid
Molecular weight:
484.64
Ref: TM-T4584
| 1mg | 63.00 € | ||
| 5mg | 137.00 € | ||
| 10mg | 187.00 € | ||
| 25mg | 341.00 € | ||
| 50mg | 567.00 € | ||
| 100mg | 810.00 € | ||
| 500mg | 1,644.00 € | ||
| 1mL*10mM (DMSO) | 145.00 € |
Estimated delivery in United States, on Monday 31 Mar 2025
